Abbott Laboratories
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $477.0M | $1.40B | $4.42B | $2.28B | $2.58B | $5.96B | $4.73B | $4.63B |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $1.05B | $803.0M | $871.0M | $918.0M | $928.0M | $1.36B | $1.40B | $1.21B |
| Amortization | $1.98B | $550.0M | $601.0M | $630.0M | $791.0M | $1.42B | $1.65B | $1.42B |
| Stock-Based Compensation | $406.0M | $310.0M | $292.0M | $246.0M | $262.0M | $433.0M | $383.0M | $387.2M |
| Net Cash from Operating Activities | $5.57B | $3.20B | $2.97B | $3.68B | $3.32B | $9.31B | $8.97B | $8.74B |
| Investing Activities | ||||||||
| Capital Expenditures | $1.14B | $1.12B | $1.11B | $1.08B | $1.15B | $1.80B | $1.49B | $1.02B |
| Business Acquisitions | $17.18B | $80.0M | $235.0M | $3.32B | $580.0M | $706.0M | $273.0M | $9.43B |
| Net Cash from Investing Activities | $-9.62B | $-248.0M | $406.0M | $-202.0M | $-3.93B | $-5.56B | $661.0M | $-12.19B |
| Financing Activities | ||||||||
| Dividends Paid | $1.85B | $1.54B | $1.44B | $1.34B | $882.0M | $3.18B | $2.94B | $2.67B |
| Stock Repurchases | $117.0M | $522.0M | $2.24B | $2.20B | $1.61B | $2.36B | $77.0M | $866.8M |
| Net Cash from Financing Activities | $-5.28B | $11.15B | $-2.24B | $-2.74B | $-6.70B | $195.0M | $-6.42B | $-1.09B |
| Net Change in Cash | $-9.21B | $13.62B | $938.0M | $588.0M | $-7.33B | $3.99B | $3.17B | $-5.16B |
| Free Cash Flow | $4.44B | $2.08B | $1.86B | $2.60B | $2.18B | $7.52B | $7.48B | $7.72B |